

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS
05 AUG 15 PM 3:59

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pfizer, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 325 7th Street, NW Suite 1200 City Washington State/Zip (or Country) DC 20004 United States			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Richard H. Bagger	Telephone 202.783.7070	E-mail (optional) Rich.Bagger@Pfizer.com	5. Senate ID # 31326-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 31354000

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-Decem

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more >> \$ _____
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more >> \$ 3,000,000
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate ex accounting method. See instructions for description of opt

Method A. Reporting amounts using LDA definition:

Method B. Reporting amounts under section 6033(b) the Internal Revenue Code

Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature _____

Date 8/2/2005

1000381071

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues


H.R. 2206, Veterinary Workforce Expansion Act of 2005 , pharmaceutical counterfeiting, importation
HR 2744, Agriculture Appropriations, pharmaceutical counterfeiting, importation
S. 914, Veterinary Workforce Expansion Act of 2005, pharmaceutical counterfeiting, importation

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Richard H.	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Boyd, Michael D.	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

0000381072

Registrant Name: **Pfizer, Inc.**

Client Name: **Pfizer, Inc.**

Item	Description	Data
18a	Lobbyist Name	Miller, Kimberly
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Wilson, Anne
18b	Covered Official Position	
18c	New Lobbyist	No

0000381073

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H. Con. Res. 95, Budget Reconciliation, pharmaceutical counterfeiting, importation

H.R. 2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation

H.R. 2862, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation

H.R. 3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation

S. Con. Res. 18, Budget reconciliation, pharmaceutical counterfeiting, importation

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Richard H.	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Boyd, Michael D.	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

0000381074

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

Item	Description	Data
18a	Lobbyist Name	Miller, Kimberly
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Wilson, Anne
18b	Covered Official Position	
18c	New Lobbyist	No

0000381075

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

H.R. 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation

H.R. 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation patent issues

S. 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation

S. 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation issues


17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Richard H.	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Boyd, Michael D.	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000381076

Signature  Date 8/2/2005

Registrant Name: **Pfizer, Inc.**

Client Name: **Pfizer, Inc.**

Item	Description	Data
18a	Lobbyist Name	Miller, Kimberly
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Wilson, Anne
18b	Covered Official Position	
18c	New Lobbyist	No

0000381077

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues

H.R. 2090, The Food and Drug Administration Improvement Act of 2005, drug safety

H.R. 3196, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety

H.R. 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety

H.R. 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation issues

H.R. 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety

S. 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation

S. 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation issues

S. 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety

S. 930, Food and Drug Administration Safety Act of 2005, drug safety

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Richard H.	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Boyd, Michael D.	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature



Date 8/2/2005

0000381078

Registrant Name: **Pfizer, Inc.**

Client Name: **Pfizer, Inc.**

Item	Description	Data
16	Lobbying Issues	Prescription and over the counter pharmaceuticals (no bills)
18a	Lobbyist Name	Miller, Kimberly
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Wilson, Anne
18b	Covered Official Position	
18c	New Lobbyist	No

000381079

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.R. 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation

H.R. 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation patent issues

S. 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation

S. 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation issues


17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Health & Human Services
Executive Office of the President
Food & Drug Administration
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Richard H.	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Boyd, Michael D.	
Carey, Christopher	
Judge, Dolly	
LaMarca, Louis A.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

0000381080

Registrant Name: **Pfizer, Inc.**

Client Name: **Pfizer, Inc.**

Item	Description	Data
18a	Lobbyist Name	McCarthy, Justin
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Miller, Kimberly
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Wilson, Anne
18b	Covered Official Position	
18c	New Lobbyist	No

0000381081

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code MMM (one per page)
- 16. Specific Lobbying issues
 - H.R. 3010, Labor, HHS Appropriations, prescription drug benefit, price controls
 - H.R. 712, Medicare Prescription Drug Sensibility Act,
 - Medicare prescription drug benefit implementation (no bills)
 - Medicaid rebates (no bills)
 - Medicaid coverage (no bills)

- 17. House(s) of Congress and Federal agencies contacted Check if None
 - Department of Health & Human Services
 - Executive Office of the President
 - House of Representatives
 - Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Richard H.	
Bennett, Catherine P.	
Carey, Christopher	
Judge, Dolly	
LaMarca, Louis A.	
Miller, Kimberly	
Wilson, Anne	

- 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

0000381082

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues
**HR 2122, The Project BioShield Act of 2003,
Pharmaceutical research and development, security**

17. House(s) of Congress and Federal agencies contacted Check if None
**Department of Commerce
Department of Health & Human Services
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bowler, M. Kenneth	
Judge, Dolly	
LaMarca, Louis A.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

1000381083



Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)


16. Specific Lobbying issues
International repatriation tax (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Boyd, Michael D.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

0000381084

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.


- 15. General issue area code TOR (one per page)
- 16. Specific Lobbying issues
 - S. 5, The Class Action Fairness Act of 2005, class action reform
 - S. 852, The Fairness in Asbestos Injury Resolution Act of 2005, asbestos litigation

- 17. House(s) of Congress and Federal agencies contacted Check if None
 - House of Representatives
 - Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Richard H.	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Boyd, Michael D.	
McCarthy, Justin	

- 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

0000381085

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

H.R. 2862, Science, State, Justice Appropriations, intellectual property, market access

H.R. 3045, Dominican Republic-Central America-United States Free Trade Agreement Implementation Act, intellectual property, foreign price controls, market access restrictions

H.R. 3283, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property, market access, foreign price controls

S. 307, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property, market access, price controls

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce

Department of State

Executive Office of the President

House of Representatives

Office of U.S. Trade Representative

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Boyd, Michael D.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/2/2005

0000381086

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

Item	Description	Data
16	Lobbying Issues	Intellectual property protection, foreign price controls and other market access restrictions (no bills) International intellectual property protection (no bills) International pharmaceutical market access (no bills) WTO accession and implementation issues (no bills)

1000381087

